Bosch John Roderick Ten Sells 1,417 Shares of Billiontoone (NASDAQ:BLLN) Stock

Billiontoone, Inc. (NASDAQ:BLLN) SVP Bosch John Roderick Ten sold 1,417 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $92.86, for a total value of $131,582.62. Following the completion of the transaction, the senior vice president owned 27,884 shares in the company, valued at approximately $2,589,308.24. The trade was a 4.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bosch John Roderick Ten also recently made the following trade(s):

• On Monday, June 29th, Bosch John Roderick Ten sold 1,416 shares of Billiontoone stock. The shares were sold at an average price of $120.00, for a total value of $169,920.00.
• On Monday, June 15th, Bosch John Roderick Ten sold 2,832 shares of Billiontoone stock. The shares were sold at an average price of $101.47, for a total value of $287,363.04.

Billiontoone Price Performance

Shares of NASDAQ:BLLN opened at $94.04 on Friday. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44. The stock’s 50 day moving average is $116.49 and its 200-day moving average is $94.60. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $4.32 billion and a price-to-earnings ratio of 134.34.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million during the quarter. Sell-side analysts forecast that Billiontoone, Inc. will post 0.83 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. BTIG Research lowered their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Guggenheim initiated coverage on Billiontoone in a report on Monday, June 29th. They set a “buy” rating and a $125.00 price objective for the company. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. dropped their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a report on Thursday, August 6th. Finally, Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $126.71.

Institutional Trading of Billiontoone

A number of hedge funds have recently bought and sold shares of the business. Adams Street Partners LLC bought a new position in Billiontoone in the 4th quarter valued at $140,063,000. Baillie Gifford & Co. purchased a new position in shares of Billiontoone in the 4th quarter worth about $103,786,000. Wasatch Advisors LP boosted its holdings in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock worth $62,160,000 after buying an additional 148,446 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Billiontoone during the fourth quarter valued at about $39,717,000. Finally, JPMorgan Chase & Co. purchased a new stake in Billiontoone during the fourth quarter worth about $32,078,000.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.